(NBIX) Neurocrine Biosciences - Ratings and Ratios

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biotechnology company specializing in the discovery, development, and commercialization of pharmaceuticals targeting neurological, neuroendocrine, and neuropsychiatric disorders. The companys portfolio includes treatments for rare and debilitating conditions, such as tardive dyskinesia, Huntingtons disease, adrenal insufficiency, and congenital adrenal hyperplasia. Its approved products include INGREZZA, the first FDA-approved treatment for tardive dyskinesia; ALKINDI, the first FDA-approved treatment for adrenal insufficiency in pediatric and adult patients; and Orilissa, a non-hormonal treatment for moderate to severe pain associated with endometriosis. Additionally, the company markets Oriahnn for moderate to severe symptoms of uterine fibroids and CRENESSITY for congenital adrenal hyperplasia.

The companys clinical pipeline focuses on addressing unmet needs in neuropsychiatric and neurological disorders. Key candidates include valbenazine for dyskinetic cerebral palsy and schizophrenia; NBI-1076986 for movement disorders; and Osavampator for major depressive disorder with inadequate response to existing treatments. Neurocrine Biosciences has established strategic collaborations with pharmaceutical companies such as AbbVie, Takeda, and Voyager Therapeutics to expand its research and development capabilities. Founded in 1992 and headquartered in San Diego, California, the company has built a reputation for innovation in CNS disorders.

Based on the provided data, here is the 3-month forecast:

Technicals: The stock is currently trading below its 20, 50, and 200-day SMAs, indicating bearish momentum. The SMA 20 at 101.09 and SMA 50 at 108.82 could act as resistance levels. Average trading volume is 1,747,718 shares over 20 days, with an ATR of 4.05, suggesting moderate volatility.

Fundamentals: With a market cap of $10.30 billion and a P/E ratio of 30.81, the stock is trading at a premium. The forward P/E of 20.41 indicates expectations of improved earnings. The P/B ratio of 3.87 reflects a higher valuation relative to book value, while the P/S ratio of 4.26 suggests moderate revenue multiples. The return on equity of 13.18% indicates decent profitability.